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Edited by Judit OvadiAbstract Genes for two structurally and functionally diﬀerent
dihydroorotate dehydrogenases (DHODHs, EC 1.3.99.11),
catalyzing the fourth step of pyrimidine biosynthesis, have been
previously found in yeast Saccharomyces kluyveri. One is closely
related to the Schizosaccharomyces pombe mitochondrial family
2 enzymes, which use quinones as direct and oxygen as the ﬁnal
electron acceptor. The other one resembles the Saccharomyces
cerevisiae cytosolic family 1A fumarate-utilizing DHODH. The
DHODHs from S. kluyveri, Sch. pombe and S. cerevisiae, were
expressed in Escherichia coli and compared for their biochemical
properties and interaction with inhibitors. Benzoates as pyrim-
idine ring analogs were shown to be selective inhibitors of
cytosolic DHODs. This unique property of Saccharomyces
DHODHs could appoint DHODH as a species-speciﬁc target
for novel anti-fungal therapeutics.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In all organisms the fourth step of pyrimidine de novo
synthesis is catalyzed by the ﬂavoenzyme dihydroorotate de-
hydrogenase (DHODH, EC 1.3.99.11). Based on subcellular
localization studies, electron acceptors and sequence similari-
ties, the known DHODH proteins are divided into two families
[1]. The family 1, which includes soluble proteins of milk
fermenting Gram-positive bacteria, Archea and a few unicel-
lular eukaryotes, is further divided into two subgroups, family
1A and family 1B (Table 1, [1–10]). The DHODH proteins
from family 1A are homodimeric, those from family 1B are
heterodimeric. The family 2 DHODHs are monomeric, either* Corresponding author. Fax: +49-6421-2865116.
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ophenol-indophenol; 3,4-DHB, 3,4-dihydroxybenzoic acid; 3,5-DHB,
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Escherichia coli or located as integral membrane proteins
facing the outer side of the inner mitochondrial membrane as
in mammals, insects, plants, and some unicellular organisms
(Table 1, [1,4,6,11–17]). In these organisms, DHODH func-
tionally links the pyrimidine biosynthetic pathway via qui-
nones to the respiratory chain and thus to molecular oxygen.
A majority of the facultative fermentative yeasts requires
small amounts of oxygen for growth even through alcohol
fermentation [18]. Saccharomyces cerevisiae contains a cyto-
solic DHODH, and is able, if supplemented with certain
compounds, to grow under strictly anaerobic conditions [19].
In contrast, Schizosaccharomyces pombe as a microaerophilic
yeast absolutely requires oxygen for growth. This is in part
related to a mitochondrially bound DHODH [4]. Some pro-
karyotic organisms, such as Lactococcus lactis [1,2] and En-
terococcus faecalis [3] contain two cytosolic DHODHs, one of
family 1A and one of family 1B (Table 1). Although the spe-
ciﬁc individual roles of these DHODHs are not precisely
known, it has been suggested that one of them may participate
in the catabolic reaction of orotate reduction [19].
The importance of suﬃcient pyrimidine nucleotide pools for
cell growth, metabolism and multiplication has determined the
biosynthetic enzymes as targets for the development of antipro-
liferative agents. In view of the enormous structural diﬀerences
between DHODH from various organisms, pharmacological
inhibitors have been already applied to reduce aberrant immu-
nological reactions [20,21], to interfere in the multiplication of
animal parasites and parasitic protozoa [22,23] and to support
antiviral therapies [24]. Candida albicans is still the major fungal
agent of human disease, but other yeasts, including S. cerevisiae
isolates, are recently of growing concern [25]. New strategies and
agents, e.g., the identiﬁcation of DHODH as an anti-fungal
target, are in the developmental stage [26–29].
Another yeast, Saccharomyces kluyveri, has recently been
intensively studied for metabolism of nucleic acid precursors.
In contrast to S. cerevisiae, both the pyrimidine and purine
catabolic pathways are present and are functional in S. kluy-
veri [30]. Through our attempts to compare the de novo py-
rimidine biosynthesis between these two yeasts and in search
for yeast-speciﬁc anti-pyrimidines, we have previously cloned
two DHODHs from S. kluyveri [6] (Table 1). From sequence
analysis and assignment to DHODH family 1 and family 2, the
diﬀerent subcellular location in this eukaryotic cell became
evident. This yeast species is apparently able to synthesizeblished by Elsevier B.V. All rights reserved.
Table 1
Protein families of DHODH
Family Organism and references Subcellular localization Electron acceptors
1 A Gram-positive bacteria Cytosolic Fumarate
L. lactis [1,2]
E. faecalis [3]
Unicellular organisms Cytosolic Fumarate
S. cerevisiae [4,5]
S. kluyveri [6]
Trypanosamatids [7,8] Cytosolic Fumarate, ?a
1 B Gram-positive bacteria Cytosolic NAD
L. lactis [1,2]
E. faecalis [3]
Bacillus subtilis [9]
Clostridium oroticum [10]
2 Gram-negative bacteria Membrane bound Quinone
E. coli [1,11]
Unicellular organisms Membrane bound Quinone
Sch. pombe [4]
S. kluyveri [6]
Toxoplasma gondii [12]
Plasmodium falciparum [13]
Plants [14], insects [15], mammals [16,17] Membrane bound Quinone
Examples from various organisms.
aDHODH from theses organisms was also shown to use molecular oxygen as electron acceptor.
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anaerobic conditions. A similar capability has been previously
created by transformation of otherwise strictly aerobic Pichia
stipidis with the S. cerevisiae URA1 gene [31].
The present biochemical characterization of the two re-
combinant S. kluyveri enzymes (Accession Nos. AF 452108
and AF 452109 in the GenBank data base) in comparison to
the recombinant DHODH from S. cerevisiae and Sch. pombe
was performed to better describe the functional role of yeast
DHODH and to deﬁne their potential value as targets for in-
hibition of the pyrimidine biosynthesis in fungi.2. Materials and methods
2.1. Materials
Special chemicals L-dihydroorotic acid, decylubiquinone (QD), 2,6-
dichlorophenol-indophenol (DCIP), and fumarate were from Sigma,
Germany. Anhydrotetracycline was from Acros, Belgium. The inhib-
itors studied were A77-1726, 2-hydroxyethylidene-cyanoacetic acid 4-
triﬂuoromethyl anilide, the active metabolite of ARAVATM (HMR
Deutschland GmbH – Aventis); brequinar sodium (NSC 368390, 6-
ﬂuoro-2-(2’-ﬂuoro-1,1’-biphenyl-4yl)-3-methyl-4-quinoline carboxylic
acid (DuPont Pharma GmbH); atovaquone, trans-2-(4-(chlorophenyl)
cyclohexyl)-3-hydroxy-1,4-naphthoquinone, 566C80 (The Wellcome
Foundation, Dartford, Kent); 3,4-dihydroxybenzoic acid (3,4-DHB)
and 3,5-dihydroxybenzoic acid (3,5-DHB, Sigma).
Synthetic oligonucleotides were from DNA Technology A/S, Aar-
hus, Denmark:
ura1for: 50CTAGTCTAGATAACGAGGGCAAAAAATGAC-
AGCCAGTTTAACTACCAAG30;
ura1rev: 50CCGCAATTGAATGCTGTTCAACTTCCCACG30;
SpDHODHfor: 50CTAGTCTAGATAACGAGGGCAAAAAAT-
GTATCAACGATCTTTGTTTCGCG30;
SpDHODHrev: 50CCGGAATTCTTCTTCCTTGCCAATTATG-
TC30;
cSkDHODH-for: 50CTAGTCTAGATAACGAGGGCAAAAAA-
TGTCTGCATCCTTAGCTATCAACT 30;
cSkDHODH-rev: 50CCGCAATTGCAGACTGTTTAACTTACC-
ACGAAATTGCTCGATCGATGTGT30;SkDHODHfor: 50CTAGTCTAGATAACGAGGGCAAAAAAT-
GCATTCAAGACCTCTACCAACAT30;
SkDHODHrev: 50TCCCCCGGGTTTACTGT TTCTCCGAT-
GATTTG30;
ZG-SkURA1Sc50: 50CTG CAT CCT TAG CTA TCA30;
ZG-SkURA1Sc30: 50TCT TAG CCA TTC CCA TGC30.
2.2. Construction of expression vectors
Cytosolic DHODH from S. cerevisiae: the ORF of the enzyme was
ampliﬁed from the plasmid pFL39 containing the URA1 gene [32] with
the primers ura1for and ura1rev. The resulting PCR fragment was cut
with XbaI/MfeI and subsequently ligated into P343 pre-cut with XbaI/
EcoRI [30,6]. The resulting plasmid was named P609 and the re-
combinant enzyme is referred to as SCcyt-DHODH. Mitochondrial
DHODH from Sch. pombe: the ORF of the enzyme was ampliﬁed
from the plasmid pFLREC1 [4] with the primers SpDHODHfor and
SpDHODHrev. The resulting PCR fragment was cut with XbaI/EcoRI
and subsequently ligated into P343, pre-cut with XbaI/EcoRI. The
resulting vector was named P610 and the recombinant enzyme is re-
ferred to as SPmt-DHODH. Cytosolic DHODH from S. kluyveri,
genomic DNA from Y057 (NRRL Y-12651) was ampliﬁed by PCR
with the primers ZG-SkURA1Sc5’ and ZG-SkURA1Sc3’. The ORF of
the enzyme was ampliﬁed from this genomic fragment with the primers
cSkDHODH-for and cSkDHODH-rev. The resulting PCR fragment
was cut with XbaI/MfeI and subsequently ligated into P343, pre-cut
with XbaI/EcoRI. The resulting vector was named P628 and the re-
combinant enzyme is referred to as SKcyt-DHODH.
Mitochondrial DHODH from S. kluyveri: the ORF of the enzyme
was ampliﬁed from plasmid P629 [6] with the primers SkDHODHfor
and SkDHODHrev. The resulting PCR fragment was cut with XbaI/
SmaI and subsequently ligated into P343, pre-cut with XbaI/SmaI. The
resulting vector was named P611 and the recombinant enzyme is called
SKmt-DHODH. The vector constructed to express the N-terminal
truncated SKmt-DHODH lacking the ﬁrst 52 amino acids was named
P612; and the recombinant enzyme is referred to as DSKmt-DHODH.
All recombinant enzymes have the 8His-tag at the C-terminus
originating from the vector P343 [33,34].
2.3. Expression and puriﬁcation of recombinant S. kluyveri,
S. cerevisiae, Sch. pombe DHODH
Transformed E. coli BL21-RP (Stratagene) strains were grown to
A600 nm ¼ 0:6–0:7 in Luria Broth medium with 100 lg/mL ampicillin.
Protein expression was induced by 200 lg/L anhydrotetracyclin and
Fig. 1. SDS–PAGE of the recombinant yeast DHODH. All DHODH
proteins were expressed as C-terminal 8His-tagged proteins and
puriﬁed on Niþ-nitrilotriacetate chromatography. M: Molecular mass
marker. Lane 1, SKmt-DHODH; lane 2, DSKmt-DHODH; Lane 3:
SKcyt-DHODH; Lane 4: SPmt-DHODH; Lane 5: SCcyt-DHODH;
(2 lg protein per lane).
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tagged proteins were gained from separation on Ni2þ–nitrilotriacetate
agarose [34]. SKmt-DHODH and SPmt-DHODH were puriﬁed in
buﬀer containing 20 mM sodium phosphate, 500 mM NaCl, and 0.1%
Triton X-100, pH 7.4, while DSKmt-DHODH, SCcyt-DHODH and
SKcyt-DHODH did not require the presence of detergents but 10%
glycerol for puriﬁcation as reported for other truncated DHODH
species [35]. Protein content was determined using the Bradford pro-
tein assay with bovine serum albumin as standard. Fractions from the
puriﬁcation procedure were analyzed by SDS–PAGE and ﬂavin
analysis was performed spectrophotometrically as described previously
[15,35]. For Western blots the proteins were handled as described [15],
using ImmobiloneP from Millipore, the enhanced chemical lumines-
cence (ECL) detection kit from Amersham, and the nitrilotriacetate-
coupled horse-radish peroxidase from Qiagen, Germany.
2.4. Enzyme assays
Activity studies of the mitochondrial DHODH were performed at 30
C in 50mMTris/HCl, 150mMKCl, and 0.1%TritonX-100, pH 8. The
oxidation of the substrate DHO with quinone as electron acceptor was
coupled with the reduction of the chromogen DCIP (600 nm, e ¼ 18 800
L M1 cm1). The detergent was omitted when cytosolic DHODHs
were assayed without the quinone but with DCIP as artiﬁcial electron
acceptor only [6,35]. The reduction of fumarate, which was suggested to
be the natural acceptor of the cytosolic enzymes [1,6], was followed by
monitoring the increase in orotate absorbance at 280 nm (e ¼ 7500 L
M1 cm1) in detergent-free buﬀer. In the presence of quinones, the
orotate determination was done at the isosbestic wavelength of QD (300
nm, e ¼ 2950 L M1 cm1). The assay buﬀer without Triton X-100 was
used for 30 mM stock solutions of 3,4-DHB, 3,5-DHB, A771726 and
brequinar sodium. 2.5 mM atovaquone was solubilized in dimethyl-
sulfoxide. The eﬀect of these compounds on yeast DHODH activity was
followed using the standard chromogen reduction assay.
2.5. Kinetic analysis
In studying the variation of the initial velocity over a range of
substrate concentrations, the concentration of all enzymes in the assays
was far below that of the substrates (approximately 107). Kinetic data
were evaluated by non-linear regression analysis using the Michaelis–
Menten equation v ¼ Vmax  ½S=ðKm þ ½SÞ as described previously
[34,35]. To determine the type of inhibition by the dihydroxybenzoates,
Vmax and Km values were determined at three diﬀerent inhibitor con-
centrations [36]. Their deviations were considered to determine whe-
ther the inhibition was competitive, uncompetitive or non-competitive.
Once the inhibition pattern was determined, the appropriate equation
for competitive inhibition v ¼ Vmax  ½S=fKm  ð1þ ½I =KicÞ þ ½Sg,
non-competitive inhibition v ¼ Vmax  ½S=fKm  ð1þ ½I=KicÞ þ ð1þ
½I=KiuÞ  ½Sg or uncompetitive inhibition v ¼ Vmax  ½S=
fKm þ ð1þ ½I =KiuÞ  ½Sg was ﬁt to the entire data set. Kic is the
competitive inhibition constant, Kiu is the uncompetitive inhibition
constant [36].
3. Results and discussion
3.1. Expression of recombinant S. kluyveri, S. cerevisiae,
Sch. pombe DHODH
Expression vectors were constructed to produce full-length
mitochondrial S. kluyveri DHODH (SKmt-DHODH), mito-
chondrial Sch. pombe DHODH (SPmt-DHODH), cytoplasmic
S. kluyveri DHODH (SKcyt-DHODH), cytoplasmatic S. ce-
revisiae DHODH (SCcyt-DHODH), and a N-terminal trun-
cated mutant of the mitochondrial S. klyuveri protein
(DSKmt-DHODH), lacking the putative bipartite mitochon-
drial targeting motif. Such a typical amino-terminal sequence
was identiﬁed to promote import (targeting sequence) and
correct insertion (transmembrane sequence) of the animal
DHODH into the mitochondrial membrane [15–17].
It was shown that similar mutants of DHODH from diﬀerent
organisms could be gained and handled without detergents for
characterization and routine inhibition studies [35]. Also, the
protein crystallization of human and rat DHODH performedto date utilized N-terminal truncated histidine-tagged frag-
ments [37,38]. Following the puriﬁcation of the full-length and
truncated yeast DHODH by metal-chelate aﬃnity chroma-
tography, the SDS–PAGE in Fig. 1 shows that protein bands of
all enzymes were of the expected molecular mass range, above
and below the 45 kDa marker protein. However, the band of
the shortened protein DSKmt-DHODH (Fig. 1, lane 2) is above
those of SKmt-DHODH and SPmt-DHODH, respectively
(Fig. 1, lanes 1 and 4). This unconventional behavior can be
explained, because the long N-terminal mitochondrial targeting
sequences of the full-size proteins contain numerous positively
charged amino acids and consequently could bind a higher
amount of SDS molecules. This elevated binding would cause a
relatively higher negative charge of the corresponding proteins.
The Western blot in Fig. 2, performed to detect speciﬁcally the
histidine-tagged proteins, shows the respective position of
the diﬀerent DHODH species. In Fig. 2 on lanes 9 and 10, the
strong bands above the 36 kDa marker protein are in agree-
ment with the value of 37.1 kDa calculated from the histidine-
tagged S.cerevisiae protein. The weak bands above the 66 kDa
marker could indicate an aggregated form of the S. cerevisiae
DHODH, although dimeric proteins are not expected in the
presence of reducing agent. The puriﬁed recombinant SCcyt-
DHODH was found to be a dimeric protein when analyzed on
Bio-Prep SE-1000/17 (BioRad) chromatography (data not
shown). A homodimer of 72 kDa was obtained from sucrose-
density-gradient centrifugation of native DHODH isolated
from S. cerevisiae [39]. Dimerization of the cytosolic family 1A
DHODH protein seems to be a characteristic feature to obtain
structure stabilization, whereas the stability is provided by in-
sertion in or attachment to the membrane in the case of the
family 2 DHODHs [11,15,17]. The yield of recombinant pro-
teins puriﬁed from 1 L of E. coli cultures was considerably
diﬀerent for the cytosolic and mitochondrial forms of yeast
DHODH when cultured under fairly identical conditions:
20 mg SCcyt-DHODH and 15 mg SKcyt-DHODH versus
2.2 mg SPmt-DHODH, 1.5 mg SKmt-DHODH. An increase in
the protein yield of the S. klyuveri enzyme was obtained from
Fig. 2. Western blot of recombinant yeast DHODH. Samples were
separated by SDS–PAGE, electrotransferred on ImmobiloneP, and
analyzed by Western blotting using nitrilotriacetate-coupled horse-
radish peroxidase for the detection of the histidine-tagged proteins in
combination with the ECL detection kit. M: molecular mass (kDa).
Lane 1, 1 lg SKmt-DHODH; lane 2, 0.2 lg SKmt-DHODH; lane 3, 1
lg nSKmt-DHODH; lane 4, 0.2 lg nSKmt-DHODH; lane 5, 1 lg
SKcyt-DHODH; lane 6, 0.2 lg SKcyt-DHODH; lane 7, 1 lg SPmt-
DHODH; lane 8, 0.2 lg SPmt-DHODH; lane 9, 1 lg SCcyt-DHODH;
lane 10, 0.2 lg SCcyt-DHODH.
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protein ratio (mol/mol) as estimated from UV–Vis analysis
varied: 0.05–0.1 (SCcyt-DHODH); 0.2–0.3 (SKcyt-DHODH);
0.6–0.9 (SPmt-DHODH), 0.15–0.2 (SKmt-DHODH); 0.4–0.6
(DSKmt-DHODH).
3.2. Kinetic characterization of the recombinant S. kluyveri,
S. cerevisiae, Sch. pombe DHODH
The speciﬁc activity of the mitochondrial yeast enzymes
using QD and DCIP as acceptors (Table 2) was in the range of
1–8 U/mg. This is considerably lower than that obtained with
other recombinant DHODH preparations, which were deter-
mined using the same assay at 30 C (84–125 U/mg for the rat
and 100–150 U/mg for the human enzyme) [34,35]. Whereas a
higher ﬂavin content could underline the elevated activity of
the truncated (DSKmt-DHODH) over the non-truncated
enzyme from S. klyuveri (Table 2), the lowest activity wasTable 2
Kinetic constants of the puriﬁed full-length and truncated yeast DHODH
Substrates DHODH Km (lM)
DHO variable+QD +DCIP SKmt 49 7
DSKmt 16.7 1.5
SPmt 257 51
DHO variable+ fumarate SKcyt 20.4 2.1
SCcyt 20 1.9
QD variable+DHO SKmt 45.3 12.3
DSKmt 213 32
SPmt 109 28
Fumarate variable+DHO Skcyt 41.6 7.4
Sccyt 115 13
The concentration of DHO was varied from 0 to 1 mM at ﬁxed concentrat
acceptors. The concentrations of QD and fumarate were varied from 0 to 0.2
mM. All measurements were done in triplicate. For Km and Vmax, the best ﬁt
given. The kcat values were calculated using the equation Vmax ¼ kcat  ½E, wh
monomer. U is the enzyme activity as lmol substrate/min.observed with the Sch. pombe DHODH despite a molar ﬂavin/
protein ratio of 0.6–0.9. In comparison to the rat and human
species (range of Km ¼ 6–15 lM for DHO and Km ¼ 9–14 lM
for QD, [34,35]), the Km values for DHO and QD (range from
50 to 260 lM, Table 2) of the mitochondrial yeast enzymes
seem to indicate an apparently lower eﬃciency of the yeast
enzymes over their counterpart in mammals. Since the con-
centration of intermediates in the pyrimidine biosynthetic
pathway in the yeast cell is not known, a signiﬁcance of this
ﬁnding for the cell growth could not be addressed.
The Km values for DHO and the acceptor fumarate given in
Table 2 with the recombinant cytosolic DHODH correlate
quite well with values reported for the puriﬁed native S. cere-
visiae enzyme, 8 lM for DHO and 45 lM for fumarate [39]. The
Km values of 100 lM for DHO and 100 lM for fumarate were
evaluated with the enzyme in yeast extracts [4]. On the basis of
5–10% FMN in the recombinant SCcyt-DHODH protein, the
kcat values (Table 2) are comparable to those of 25 s1 (DHO
varied) and 23 s1 (fumarate varied) reported for the native
DHODH [39]. The cytosolic DHODH from S. kluyveri is very
similar in its kinetic properties to that of S. cerevisiae (Table 2).
3.3. Inhibition of the recombinant S. kluyveri, S. cerevisiae,
Sch. pombe DHODH
Speciﬁc inhibitors for yeast DHODH have not been de-
scribed yet. Therefore, we studied the recombinant enzymes
from S. kluyveri, S. cerevisiae, and Sch. pombe for their sus-
ceptibility to various compounds, which have already been
proven as potent inhibitors of DHODHs from other species.
The cinchoninic derivative brequinar was originally developed
as cytostatic agent, the malononitrilamide A77-1726 has an
anti-inﬂammatory eﬃcacy proﬁle and the naphthoquinone
atovaquone received clinical approval to combat Plasmodium
falciparum and Pneumocystis carinii.
From Table 3, it can be seen that brequinar and A77-1726
had to be applied in the millimolar range in order to cause a
10–20% reduction of activity with the cytosolic DHODH from
S. kluyveri, S. cerevisiae and a 20–70% decrease with the mi-
tochondrial enzymes from S. kluyveri and Sch. pombe. Inter-
estingly, 250 lM of the naphthoquinone atovaquone already
caused about 50% inhibition of the cytosolic DHODH and the
N-terminal truncated mitochondrial mutant from S. kluyveri
although its naphthoquinone ring mimics the ubiquinone andVmax (U/mg) kcat (s1) kcat=Km (M1 s1)
3 0.13 2.5 5.1 104
7.7 0.2 5.7 3.4 105
1.2 0.08 1 3.9 103
4.3 0.1 2.6 1.3 105
3.4 0.8 2.1 1.1 105
0.4 0.04 0.34 7.5 103
4.9 0.5 3.6 1.7 104
2 0.3 1.7 1.6 104
4.5 0.2 2.7 6.4 104
3.8 0.1 2.3 2 104
ions of 100 lM QD and 60 lM DCIP or 1 mM fumarate as electron
mM and 0 to 1 mM, respectively, at a ﬁxed DHO concentration of 1
(asymptotic S.E.M.) of the Michaelis–Menten equation to all data is
ere [E] is the total enzyme concentration and is based on one active site/
Table 4
Mechanism of inhibition by hydroxybenzoates of recombinant cyto-
solic S. cerevisiae and S. kluyveri DHODH
Inhibitor SCcyt-DHOD
Kic (lM)
SKcyt-DHOD
Kic (lM)
Type of inhibiton
3,4-DHB 381 110 98 22 Competitive
3,5-DHB 327 98 115 42 Competitive
Inhibitor constants for competitive inhibition Kic were determined by
measuring the initial velocities with varying concentrations of 1–1000
lM DHO and three concentrations of 3,4-DHB (0; 0.5; 3.0; 6.0 mM)
and 3,5 DHB (0; 0.5; 1.5; 3.0 mM). The constants (asymptotic
S.E.M) are derived from best ﬁts to all data.
Table 3
Activity of recombinant yeast DHODH in the presence of putative inhibitors
DHO (mM) Inhibitor SCcyt-DHODH SKcyt-DHODH DSKmt-DHODH SKmt-DHODH SPmt-DHODH
1 3 mM 3,4-DHB 77 59 84 92 87
0.1 3 mM 3,4-DHB 42 13 72 87 n.d.
0.01 3 mM 3,4-DHB 6 5 99 63 n.d.
1 3 mM 3,5-DHB 67* 44 95 68 100*
0.1 3 mM 3,5-DHB 24 12 68 85 n.d.
0.01 3 mM 3,5-DHB 9 12 100 81 n.d.
1 3 mM A77-1726 85 91 66 82 81
1 3 mM brequinar 81 85 59 76 32
1 0.25 mM atovaquone 51 50 55 66 89*
Relative velocities determined in chromogen reduction assays with 1 mM dihydroorotate and 0.1 mM DCIP as ﬁnal electron acceptor are given. The
reaction velocity of each enzyme without inhibitor was set as 100%. Values are means of three determinations which varied 2–15% of the mean; (*),
20–30% of the mean, respectively.
n.d., not determined.
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drial DHODH from mammals [36]. The benzoates 3,4-DHB
and 3,5-DHB were shown only recently to inhibit the family
1A DHODH from Lactococcus lactis in a competitive mode of
action, with 32 lM dihydroorotate and 1 mM of these com-
pounds [40]. Here, at high concentrations only 3,5-DHB was
able to depress the enzyme activity of Skcyt-DHOD to less
than 50%. By lowering the DHO concentration in the enzyme
assays both, 3,4-DHB and 3,5-DHB, inhibited the cytosolic
DHODH of S. kluyveri and S. cerevisiae by more than 90%
(Table 3), whereas the same variation in DHO concentrations
did not cause a signiﬁcant decrease in activity of the mito-
chondrial DHODH. The two dihydroxybenzoates did not
suppress the activity of recombinant human DHODH at a
concentration up to 2 mM (unpublished data). This implies
that the two benzoates and pyrimidine-ring analogs are selec-
tive inhibitors of family 1A DHODH. From kinetic analysis
(Tables 3 and 4), 3,4-DHB and 3,5-DHB were evaluated as
competitive inhibitors with Ki values in the lM range. Since
these were lower with SKcyt-DHODH, it can be deduced that
both benzoates mimic the DHO binding more eﬀectively with
the S. kluyveri enzyme than with DHODH from S. cerevisiae.
Concluding remarks. The existence of two diﬀerent
DHODHs within the same eukaryotic cell with distinct
subcellular location has been proven [6]. Both DHO-
DHs and a truncated mutant from S. kluyveri, as well as
the enzymes from S.cerevisiae and Sch. pombe, are now
available as recombinant proteins for the evaluation of
drug eﬃcacy in relation to that observed or expected
with the animal and human DHODH.The dissimilarities between family 1 and family 2 DHODH
of diverse organisms, and the marked species speciﬁc eﬃciency
of DHODH inhibitors, shown in the present study and in the
previous work [14,15,27,35,36], would appoint the fourth
enzyme of pyrimidine biosynthesis as a promising target for
speciﬁc chemotherapeutic attack in yeast.
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